AbbVie raised its full-year adjusted earnings forecast October 30 after reporting third-quarter revenue of $17.404 billion, up 10.3% from a year earlier.
Reported diluted earnings per share were $2.37. Adjusted diluted earnings, which exclude specified items, were $3.82 per share. Both measures included an unfavorable 11-cent impact from acquired research-and-development and milestone expenses.
The company now expects 2026 adjusted earnings of $13.95 to $13.99 per share, compared with its previous $13.76 to $13.96 range. That forecast includes 69 cents per share in acquired research-and-development and milestone costs recorded through September.
Immunology sales increased 16.3% to $9.165 billion. Skyrizi generated $5.776 billion and Rinvoq $2.706 billion, while Humira sales declined 31.2% to $683 million.
Neuroscience revenue rose 19.4% to $3.389 billion. Aesthetics revenue declined 1.4% to $1.176 billion.
AbbVie also increased its quarterly dividend from $1.73 to $1.82 per share, starting with the payment scheduled for February 16, 2027. The record date is January 15.
Sources: Company — October 30 Announcement: https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2026-financial-results-302924866.html